Joshua, Anthony M.

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 3,028

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,774

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,633

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,069

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine

Ocular Oncology and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 924

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 665

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 230

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., et al. (2024) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 195

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 167

Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma

Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., et al. (2016) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 109

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 72

Carney complex with adrenal cortical carcinoma

Morin, E., Mete, O., Wasserman, J. D., Joshua, A. M., Asa, S. L., & Ezzat, S. (2012) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research Advances

Cited by 69

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

Shenderov, E., Mallesara, G. H. G., Wysocki, P. J., Xu, W., Ramlau, R., Weickhardt, A. J., Zolnierek, J., Spira, A., Joshua, A. M., Powderly, J., et al. (2021) · Annals of Oncology

Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and Inhibitors

Cited by 28

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER

Joshua, A. M., Armstrong, A., Crumbaker, M., Scher, H. I., de Bono, J., Tombal, B., Hussain, M., Sternberg, C. N., Gillessen, S., Carles, J., et al. (2022) · European Journal of Cancer

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 28

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Marastoni, S., Madariaga, A., Pesic, A., Nair, S. N., Li, Z. J., Shalev, Z., Ketela, T., Colombo, I., Mandilaras, V., Cabanero, M., et al. (2022) · Cancer Research Communications

Ovarian cancer diagnosis and treatmentAutophagy in Disease and Therapy

Cited by 19

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 12

A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.

Lau, B., Crumbaker, M., Yam, A. O. W., Marastoni, S., Luckhurst, M., O'Grady, A., Wouters, B., & Joshua, A. M. (2021) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 3

Abstract A029: Re-purposing non-oncology agent itraconazole to target the dynamic cellular ecosystem of pancreatic cancer

Chacon-Fajardo, D., Porazinski, S., Man, J., Yim, H., El-Omar, E., Joshua, A., & Pajic, M. (2024) · Cancer Research

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 1